Genmab A/S
NASDAQ: GMAB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jan van de Winkel
- Employees
- 2,638
- Headquarters
- Copenhagen, Denmark
- IPO year
- 2009
- Market cap
- $15.5B
- Website
- https://www.genmab.com
Loading GMAB…
Loading profile data…Frequently asked questions about GMAB
What does Genmab A/S (GMAB) do?
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human mo...
Where does GMAB trade?
Genmab A/S (GMAB) trades on the NASDAQ Global Select.
What sector is GMAB in?
Genmab A/S (GMAB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Genmab A/S?
Jan van de Winkel is the chief executive officer of Genmab A/S (GMAB).
Where is Genmab A/S headquartered?
Genmab A/S is headquartered in Denmark.
Does GMAB pay a dividend?
Genmab A/S (GMAB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GMAB go public?
Genmab A/S (GMAB) completed its initial public offering in 2009.
Is GMAB an ADR?
Yes — GMAB is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Genmab A/S reporting and dividends follow the underlying issuer.